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Background: Several studies have investigated single nucleotide polymorphisms (SNP) in candi-
date genes associated with susceptibility, severity or outcome in patients with community-
acquired pneumonia (CAP) with conflicting results.
Methods: Multi-centre, prospective observational study.We studied 1162white Spanish patients
with CAP and 1413 controls. Severe forms of sepsis were recorded in 325 patients. Subjects were
genotyped for the following polymorphisms: TNF 238 and 308, LTA þ252, IL6 174, IL1RN
86 bp variable number of tandem repeats and TNFRSF1B þ 676 (TNFR2 M196R).28 449 511; fax: þ34 928 449293.
ecanarias.org (C. Rodriguez-Gallego).
9 Elsevier Ltd. All rights reserved.
Genetics in community-acquired pneumonia 441Results: No significant differences in genotype or allele frequencies were seen among patients
and controls. We did not find any association between TNF, LTA, IL6 and IL1RN polymorphisms
with disease severity or outcome. Analysis of 28-day mortality showed a significant difference
in the distribution of TNFRSF1B þ 676 G/T genotypes (pZ 0.0129). Sequential KaplaneMeier
survival analysis of TNFRSF1B þ 676 G/T polymorphism showed a protective role of the GT geno-
type. Cox regression analysis adjusted for age, gender, hospital of origin and comorbidities
showed that patients with GT genotypes had lower mortality rates compared to patients with
GG or TT genotypes (pZ 0.02; HR 0.53; 95% CI 0.31e0.90 for 90-day survival; pZ 0.01; HR
0.41; 95% CI 0.21e0.81 for 28-day survival and pZ 0.049; HR 0.48; 95% CI 0.23e0.997 for 15-
day survival).
Conclusions: Our studydoes not support a role for the controversial studiedpolymorphisms of the
TNF, LTA, IL6 and IL1RN genes in the susceptibility or outcome of CAP. A protective role
of heterozygosity for the functionally relevant TNFRSF1B þ 676 polymorphism in the outcome
of CAP was observed.
ª 2009 Elsevier Ltd. All rights reserved.Introduction
The clinical presentation of community-acquired pneu-
monia (CAP) varies widely.1 Several factors may play
a role to account for this variability. Different patho-
gens, variable virulence in different strains of microor-
ganisms, increasing age, and underlying diseases
undoubtedly have an important impact, but genetic
variability affecting the host response may also influence
the susceptibility to it and the severity and outcome of
infection.2
Severe sepsis (SS) is common in hospitalized CAP
patients, and is the leading cause of death in these
patients. Since deregulation of innate immunity is
believed to be central to the manifestation of sepsis,
studies of genetic susceptibility and outcome of septic
shock (SSh) have focused on genes involved in inflamma-
tory pathways.
The need for early and definite diagnosis of sepsis, as
well as the identification of patients at risk for poor prog-
nosis, resulted in the proposition of a staging system:
predisposition, insult, response and organ dysfunction
(PIRO).3 Several polymorphisms in cytokine genes have
been associated with an increased risk of developing or
dying from SSh,4 and genetic variability has been suggested
to be included as a new variable in the predisposition and
response sections of PIRO. However, contradictory findings
about the role of several genetic variants in sepsis have
been reported, and it has usually been proved difficult to
reproduce initial results. Several methodological problems
may explain many of the discrepancies, including limited
statistical power, heterogeneous populations with unrec-
ognized confounding factors, misleading definition of
phenotype, the presence of linkage disequilibrium, and the
stratification of populations.5
The aim of this multi-centre study was to recruit an
ethnically homogeneous large group of patients with
CAP in order to investigate whether common poly-
morphisms within genes encoding for inflammatory or
anti-inflammatory molecules are associated with
susceptibility, severity of illness or outcome in adult
patients with CAP.Methods
Patients and controls
A total of 1162 white Spanish patients with CAP, hospital-
ized at four university hospitals in Spain (Gran Canaria,
Madrid, Valencia and Huesca) were prospectively included
in the study. The diagnosis of pneumonia was based on the
presence of acute onset of signs and symptoms suggesting
lower respiratory tract infection on admission, and radio-
graphic evidence of a pulmonary infiltrate that had no other
known cause. Patients with defined severe immunosup-
pression, and patients with tuberculosis, obstructive
pneumonia caused by neoplasia or pneumonia as terminal
event of chronic and progressive disease, were excluded
from the study. The control group consisted of 1413 unre-
lated healthy volunteers and patients without a previous
history of relevant infectious diseases (49.04  17.40 years,
43.1% women). Sepsis, SS, SSh and multiple organ
dysfunction syndrome (MODS) were defined using the
American College of Chest Physicians/Society of Critical
Care Medicine criteria.6 The pneumonia severity index (PSI)
was measured using the Fine scale.7 Acute respiratory
failure (ARF) was defined as an oxygen saturation of less
than 90% on room air, or a PaO2 less than 60 mmHg. Acute
respiratory distress syndrome (ARDS) was defined by using
the American European Consensus Conference Definition.8
In patients admitted on the intensive care unit (ICU),
severity of illness was evaluated by the Acute Physiology
and Chronic Health Evaluation (APACHE) II score, taking the
worst reading of the first 24 h in the ICU.9
Genotyping
Genotypes for tumor necrosis factor-a (TNF ) 238 (rs
361525), TNF 308 (rs 1800629) and lymphotoxin-a (LT-a)
þ252 (rs909253) were determined by real-time polymerase
chain reaction as previously reported.10 Genotyping for TNF
receptor-2 (TNFRSF1B) þ676 (M196R; rs1061622), inter-
leukin-6 (IL6) 174 (rs1800795) and the variable number of
tandem repeat (VNTR) of 86 bp in interleukin-1 receptor
442 J. Sole´-Viola´n et al.antagonist (IL1RN; intron 2), were carried out using minor
modifications of previously described procedures.11e13 The
accuracy of SNP genotyping was confirmed by direct
sequencing in an ABI Prism 310 (Applied Biosystems)
sequencer. Alleles of the VNTR 86 bp are termed according
to the rank of frequencies in healthy individuals; alleles 1,
2, 3, 4 and 5 represent four repeats, two repeats, five
repeats, three repeats and six repeats of 86 bp tandem
repeat. Informed consent was obtained from the patients
or their relatives. The protocol was approved by the local
ethics committee of the four hospitals. Research that is
reported in the manuscript is in compliance with the Hel-
sinki Declaration.
Statistical analysis
HardyeWeinberg equilibrium for each single nucleotide
polymorphism (SNP) and linkage disequilibrium (LD, D0) was
calculated with arlequin version 3.11 software. Quantita-
tive variables are presented using arithmetic mean  SEM.
Genotype distribution was compared using c2 test or Fisher
exact test when needed, and odds ratios (OR) with 95% of
confidence intervals (95% CI) were calculated. The relation
between severity or outcome with genotypes was evaluated
by binary logistic regression models. Age, gender, hospital
of origin and co-morbidities were included as independent
variables for multivariate analysis. Survival rates were
estimated using the KaplaneMeier method and their
comparison related to genotypes was performed with log-
rank test. Multivariate analysis adjusted for age, gender,
hospital of origin and co-morbidities was carried out with
Cox proportional hazard model. Statistical analysis was
performed using SPSS 15.0 (SPSS, Inc, Chicago, IL).
Results
Between January 2002 and September 2007, patients
admitted to four different Spanish University Hospitals
were evaluated for the diagnosis of CAP. After excluding
those patients without informed consent, those with
ethnicity other than white Spanish, and those who fulfilled
the exclusion criteria, a total of 1162 patients were finally
included. The main demographic and clinical variables of
the patients are showed on Table 1.
Microbiological documentation of CAP was achieved in
614 patients (55.6%) Streptococcus pneumoniae was the
most common etiologic agent (288, 26%; 46.9% of the
patients with known causative microorganism), Pseudo-
monas aeruginosa was isolated in 26 patients (2.4%), Hae-
mophilus influenzae in 17 (1.5%) and Staphylococcus aureus
in 19 (1.7%). Other causative microorganisms were identi-
fied in 264 patients. One hundred and seven patients (9.2%)
had positive blood cultures.
Empirical antibiotic therapy was according to ATS/IDSA
guidelines in 95.5% of the patients. The mortality of these
patients was 4.16% compared to 7.17% in those without
guidelines adherence. No differences in appropriate
antibiotic use were observed when stratifying
patients based on severity or outcome: SS and SSh, 95.2
and 93.0%, respectively; ARF, 95.6%, ARDS 97.7%; and
90-day mortality 98.6%.Distribution of genotypes of the 1162 patients and
controls are summarized in Table 2. Genotype frequencies
of the studied polymorphisms in the control group were in
HardyeWeinberg equilibrium. No significant differences in
genotype or allele frequencies were seen between the two
groups. We did not find either any association between TNF,
LTA, IL6 and IL1RN polymorphisms with disease severity or
outcome (Table 3), even when severe forms of sepsis
(NZ 325) were considered (data not shown). A trend
toward LTA þ252 A homozygous individuals to MODS
(pZ 0.048, ORZ 1.44, 95% CI 0.99e2.12) was observed.
The TNF 308 and 238 and the LTA þ252 single nucleotide
polymorphisms (SNP) were found to be in LD in the control
group (D0 for the SNP pairs TNF 238/308, TNF 238/LTA
þ252 and TNF 308/LTA þ252 were 0.87, 0.79 and 0.85,
respectively (p < 0.001 for the three analysis). No associa-
tion with susceptibility or outcome was observed when
allelic and genotypic frequencies of the combined TNF and
LTA SNPs were compared (data not shown).
When the TNFRSF1B þ 676 SNP was analysed, carriage of
the G allele was found to be increased in patients who
developed MODS (Table 3) and ARDS (data not shown),
although the differences did not achieve statistical signif-
icance (pZ 0.048, ORZ 1.43, 95% CI 0.98e2.07 and
pZ 0.085, ORZ 1.68, 95% CI 0.88e3.21, respectively). In
the 28-day mortality analysis, a statistically significant
difference in the distribution of TNFRSF1B þ 676 G/T
genotypes was observed (pZ 0.0129 for the 3  2 anal-
ysis). However, a protective role against fatal outcome of
the heterozygous genotype, compared to homozygosity
for the T and G alleles was now found (pZ 0.006,
ORZ 0.39, 95% CI 0.17e0.8 and pZ 0.026, ORZ 0.55, 95%
CIZ 0.30e0.95 for 28- and 90-day mortality, respectively).
In fact, an increased frequency of individuals homozygous
for both alleles was observed among non-survivors
compared to survivors, although these differences did not
achieve statistical significance (pZ 0.046, ORZ 1.83, 95%
CI 0.98e3.6, and pZ 0.18 for homozygosity for T and G
alleles vs the rest of genotypes, respectively). Due to the
apparently contradictory results in the susceptibility to
MODS and ARDS to the predisposition to fatal outcome, we
first analysed 28-day death among individuals with MODS
and ARDS (data not shown). Heterozygosity for
TNFRSF1B þ 676 was found to be protective against 28-day
death in patients with MODS (pZ 0.02, ORZ 0.36, 95% CI
0.13e0.91), and a non-significant trend was observed
in patients with ARDS (pZ 0.037, ORZ 0.22, 95% CI
0.03e1.12). A predisposition to mortality among MODS
patients was found to be associated with homozygosity for
the G allele (pZ 0.02, ORZ 5.92, 95% CI 1.06e39.72);
homozygosity for the T allele was also found to be
increased in patients who died, although these differences
did not achieve statistical significance. A similar distribu-
tion of genotypic frequencies was observed in patients with
ARDS, although due to the small number of patients, no
significant association of the individual homozygous geno-
types with mortality was observed. We then conducted
a sequential KaplaneMeier survival analysis of the three
different TNFRSF1B þ 676 genotypes in the complete group
of CAP patients at 15, 28 and 90 days (Figure 1). Cox
regression analysis adjusted for age, gender, hospital of
origin and comorbidities showed that patients with GT
Table 1 Demographic and clinical characteristics of CAP
patients.
Characteristics n (%)
Age 63.73  17.82*
Sex
Male 763 (65.6)
Female 399 (34.3)
Co-morbidityy
No 390 (33.5)
COPD 332 (28.5)
Asthma 58 (4.9)
Neoplasy 128 (11.0)
Ischemic cardiopathy 125 (10.7)
Diabetes 264 (22.7)
Renal insufficiency 92 (7.9)
Hepatic insufficiency 67 (5.7)
Neurological pathology 157 (13.5)
Autoimmune pathology 33 (2.8)
Psychiatric pathology 8 (0.6)
ICU admission
No 897 (77.2)
Yes 265 (22.8)
Pneumonia severity index
IeIII (low) 523 (45.0)
IVeV (moderateehigh) 639 (55.0)
Acute respiratory failure
No 394 (33.9)
Yes 768 (66.1)
ARDS
No 1115 (96.0)
Yes 47 (4.0)
Bacteraemia
No 1055 (90.8)
Yes 107 (9.2)
Sepsis
Non-severe sepsis 837 (72.0)
Severe sepsis 160 (13.8)
Septic shock 165 (14.2)
MODS
No 1021 (87.9)
Yes 141 (12.1)
28-day exitus
No 1104 (95.0)
Yes 58 (5.0)
90-day exitus
No 1082 (93.1)
Yes 80 (6.9)
* For age the value is media  standard deviation.
y Some patients had more than one co-morbidity. CAP,
community-acquired pneumonia; COPD, chronic obstructive
pulmonary disease; ICU, intensive care unit; ARDS, acute
respiratory distress syndrome; Non-severe sepsis, patients
without either severe sepsis or septic shock; MODS, multiple
organ dysfunction syndrome.
Table 2 Genotype frequencies of the studied poly-
morphisms in patients and controls.
CAP patients Controls
TNF 238 NZ 1135 NZ 1172
G/G 976 (85.99) 1016 (86.69)
G/A 151 (13.30) 153 (13.05)
A/A 8 (0.71) 3 (0.26)
TNF 308 NZ 1136 NZ 1152
G/G 856 (75.35) 870 (75.52)
G/A 258 (22.71) 260 (22.57)
A/A 22 (1.94) 22 (1.91)
LTA þ252 NZ 1120 NZ 1228
A/A 566 (50.54) 621 (50.57)
A/G 471 (42.05) 511 (41.61)
G/G 83 (7.41) 96 (7.82)
TNFRSF1B þ 676 NZ 1107 NZ 1071
T/T 677 (61.16) 636 (59.38)
T/G 379 (34.24) 381 (35.57)
G/G 51 (4.61) 54 (5.04)
IL1RN VNTR 86 bp NZ 1152 NZ 1223
1/1 576 (50.00) 587 (48.00)
1/2 416 (36.11) 481 (39.33)
1/3 31 (2.69) 30 (2.45)
1/4 6 (0.52) 12 (0.98)
1/5 2 (0.17) 1 (0.16)
2/2 107 (9.29) 97 (7.93)
2/3 9 (0.78) 11 (0.90)
2/4 3 (0.26) 3 (0.25)
3/3 2 (0.17) 1 (0.08)
IL6 174 NZ 1138 NZ 1215
G/G 533 (46.8) 590 (48.56)
G/C 485 (42.6) 502 (41.32)
C/C 120 (10.5) 123 (10.12)
Values are the number (%). N, number of patients. CAP,
community acquired pneumonia. Gene nomenclature: TNF,
tumor necrosis-a; LTA, lymphotoxin-a; TNFRSF1B, tumor
necrosis factor alfa receptor-2; IL1RN VNTR, variable number of
tandem repeat in interleukin-1 receptor antagonist; IL6, inter-
leukin-6.
Genetics in community-acquired pneumonia 443genotypes had lower mortality rates compared to those
patients with GG þ TT genotypes (pZ 0.02, HR 0.53, 95%
CI 0.31e0.90 for 90-day survival; pZ 0.01, HR 0.41, 95% CI
0.21e0.81 for 28-day survival and pZ 0.049, HR 0.48, 95%
CI 0.23e0.997 for 15-day survival).Discussion
In this study,wehaveobserveda significantly lower frequency
of individuals heterozygous for the TNFRSF1B þ 676 T/G SNP
among those with fatal outcome compared to survivals, thus
supporting a potential role of this polymorphism in the path-
ophysiology of CAP. To our knowledge this is the first report
studying the role of TNFRSF1B alleles in patients with CAP. On
the other hand, we did not confirm previous associations of
the studied polymorphisms of TNF, LTA, IL6 and IL1RN with
susceptibility to or severity and outcome of CAP.
Seminal studies in mice showed the key role of cytokines
in sepsis.14 In humans, conflicting results have been
reported for TNF, LTA, IL6 and IL1RN polymorphisms in
sepsis: TNF 308 and 238 were associated to disease
severity and outcome in some studies15e18 but not in oth-
ers.19e22 Controversy also exists regarding the role of the
LTA þ25220,23e25 and IL6 174.25e28 The IL1RN*2 allele has
been reported to be associated with susceptibility or poor
Table 3 Associations between genotype, disease severity and outcome.
SEPSIS MODS 28-day exitus 90-day exitus
NSS SS SSh No Yes No Yes No Yes
TNF 238 (NZ 1135)
G/G 694 (85) 138 (86.25) 144 (90) 857 (85.9) 119 (86.2) 927 (85.9) 49 (85.9) 908 (85.9) 68 (86.0)
G/A 117 (14.4) 20 (12.5) 14 (8.75) 134 (13.4) 17 (12.3) 144 (13.3) 7 (12.2) 142 (13.5) 9 (11.3)
A/A 4 (0.5) 2 (1.25) 2 (1.25) 6 (0.6) 2 (1.4) 7 (0.6) 1 (1.7) 6 (0.5) 2 (2.5)
TNF 308 (NZ 1136)
G/G 610 (77.6) 124 (77.5) 122 (76.2) 747 (74.8) 109 (78.9) 812 (75.2) 44 (77.1) 794 (75.1) 62 (78.4)
G/A 188 (23.9) 35 (21.8) 35 (21.8) 230 (23.0) 28 (20.2) 245 (22.7) 13 (22.8) 241 (22.8) 17 (21.5)
A/A 18 (2.2) 1 (0.6) 3 (1.8) 21 (2.1) 1 (0.7) 22 (2.0) 0 (0) 22 (2.0) 0 (0)
LTA þ252 (NZ 1120)
A/A 400 (49.7) 79 (50.3) 87 (54.7) 487 (49.4) 79 (58.5)* 539 (50.7) 27 (47.3) 527 (50.6) 39 (49.3)
A/G 343 (42.6) 64 (40.7) 64 (40.2) 421 (42.7) 50 (37.0) 446 (41.9) 25 (43.8) 436 (41.8) 35 (44.3)
G/G 61 (7.5) 14 (8.9) 8 (5.0) 77 (7.8) 6 (4.4) 78 (7.3) 5 (8.7) 78 (7.4) 5 (6.3)
TNFRSF1B þ 676 (NZ 1107)
T/T 478 (60.8) 104 (65.0) 95 (59.0) 602 (62.2) 75 (53.5) 635 (60.4) 42 (73.6) 622 (60.5) 55 (69.6)
T/G 272 (34.6) 50 (31.2) 57 (35.4) 322 (33.2) 57 (40.7)y 369 (35.1) 10 (17.5)z 361 (35.1) 18 (22.7)z
G/G 36 (4.5) 6 (3.7) 9 (5.5) 43 (4.4) 8 (5.7)y 46 (4.3) 5 (8.7) 45 (4.3) 6 (7.5)
IL1RN VNTR 86 bp (NZ 1152)
1/1 423 (51.0) 72 (45.0) 81 (49.3) 504 (49.8) 72 (51.0) 545 (49.8) 31 (53.4) 537 (50.0) 39 (48.7)
1/2 300 (36.2) 61 (38.1) 55 (33.5) 366 (36.2) 50 (35.4) 393 (35.9) 23 (39.6) 381 (35.5) 35 (43.7)
1/3 14 (1.6) 11 (6.8) 6 (3.6) 26 (2.2) 5 (3.5) 30 (2.7) 1 (1.7) 29 (2.7) 2 (2.5)
1/4 3 (0.3) 1 (0.6) 2 (1.2) 5 (2.5) 1 (0.7) 5 (0.4) 1 (1.7) 5 (0.4) 1 (1.2)
1/5 2 (0.2) 0 (0) 0 (0) 2 (0.1) 0 (0) 2 (0.4) 0 (0) 2 (0.1) 0 (0)
2/2 77 (9.2) 13 (8.1) 17 (10.3) 97 (9.5) 10 (7.08) 105 (9.5) 2 (3.4) 104 (9.7) 3 (3.7)
2/3 5 (0.6) 1 (0.6) 3 (1.8) 6 (0.5) 3 (2.1) 9 (0.8) 0 (0) 9 (0.8) 0 (0)
2/4 2 (0.2) 1 (0.6) 0 (0) 3 (0.2) 0 (0) 3 (0.2) 0 (0) 3 (0.2) 0 (0)
3/3 2 (0.2) 0 (0) 0 (0) 2 (0.1) 0 (0) 2 (0.1) 0 (0) 2 (0.1) 0 (0)
IL6 174 (NZ 1138)
G/G 392 (47.9) 73 (45.9) 68 (41.9) 474 (47.3) 59 (43.0) 512 (47.3) 21 (36.8) 504 (47.5) 29 (36.7)
G/C 341 (41.7) 68 (42.7) 76 (46.9) 423 (42.2) 62 (45.2) 457 (42.2) 28 (49.1) 446 (42.1) 39 (49.3)
C/C 84 (10.2) 18 (11.3) 18 (11.1) 104 (10.3) 16 (11.6) 112 (10.3) 8 (14,0) 109 (10.2) 11 (13.9)
Data are number of patients and percentage. N, number of patients with available data; NSS, non-severe sepsis; SS, severe sepsis; SSh,
septic shock; MODS, multiple organ dysfunction syndrome. Gene nomenclature: TNF, tumor necrosis-a; LTA, lymphotoxin-a; TNFRSF1B,
tumor necrosis factor alfa receptor-2; IL1RN VNTR, variable number of tandem repeat in interleukin-1 receptor antagonist; IL6,
interleukin-6.
* A/A vs A/G þ G/G; pZ 0.048, ORZ 1.44, 95% CI 0.99e2.12.
y T/G þ G/G vs T/T; pZ 0.048, ORZ 1.43, 95% CI 0.98e2.07.
z T/G vs T/T þ G/G; pZ 0.006, ORZ 0.39, 95% CI 0.17e0.8 and pZ 0.026, ORZ 0.55, 95% CI 0.30e0.95 for 28- and 90-day mortality,
respectively.
444 J. Sole´-Viola´n et al.outcome of sepsis.23,29e30 However, a non-significant
decrease of homozygosity for the IL1RN*2 allele was even
observed among non-survivors in our survey. These results
were not replicated in our study, and even a non-significant
association of homozygosity for the LTA þ252 A allele with
the development of MODS was observed.
As far as we know, only three studies focusing on these
genes have been conducted in CAP patients so far. Waterer
et al.16,24 in two studies conducted in a relatively small
group of patients found that homozygosity for the LTA þ252
A allele was a risk factor for SSh, whereas respiratory
failure, in the absence of shock, strongly correlated with
homozygosity for the LTA þ252 G allele. Gallagher et al.25
did not find any association of the SNPs TNF 308 and IL6
174 SNPs with susceptibility and severity. Possible expla-
nations for the discrepancies include limited statistical
power, heterogeneous patient populations withunrecognized confounding factors, and stratification of
population substructure and/or imprecise definitions of
phenotype. These limitations, evident in many of the
above-mentioned studies, rendered their interpretation
problematic.
Compared to previous works, our study has several
strengths. First, our large cohort of patients with CAP
reduces the type I error. Second, the prospective design
helps minimize phenotype misclassification. Third, we
performed a multicenter study including only adult Span-
iard Caucasian patients and controls. Fourth, genetic data
were compared not only between patients and healthy
controls, but also, and even more importantly, between
patients with and without the studied clinical phenotypes.
Fifth, whereas most of the aforementioned studies involved
a mixed group of critically ill patients with sepsis, we have
studied hospitalized patients with the only diagnosis of CAP.
Figure 1 KaplaneMeier survival analysis of patients with
community-acquired pneumonia according to TNFRSF1B þ 676
G/T genotypes. Individuals with G/T genotype are represented
by a dashed line, those with T/T genotype by a thin line and
those with G/G genotype by a thick line. e 90-day survival:
long rank c2; pZ 0.016. Regression Cox* (pZ 0.02, HR 0.53,
95% CI 0.31e0.9). e 28-day survival: Regression Cox* (pZ 0.01;
HR 0.41, 95% CI 0.21e0.81). e 15-day survival: Regression Cox*
(pZ 0.049; HR 0.48, 95% CI 0.23e0.99). * adjusted for the
independent variables age, gender, hospital of origin and
co-morbidities.
Genetics in community-acquired pneumonia 445Finally, we have also evaluated the impact of the genetic
variants in the severity and CAP mortality after controlling
for different confounding variables already known to affect
outcome.
In our sequential study of death associated to
TNFRSF1B þ 676 genotypes, we have observed a significant
association when 15-, 28- and 90-day mortality was studied.
TNFR1 and TNFR2 receptors mediate biological activity
of TNF-a and LT-a. Both receptors activate distinct signal
transduction pathways, which may explain their shared and
diverse functions.31 TNFR2 signalling is not well character-
ized, but it has been shown to mediate signals that promote
tissue repair and angiogenesis.31 In addition, a role of
TNFR2 in apoptosis, cell activation, migration or prolifera-
tion in cultured cells has been reported.31e32 Under certain
circumstances, TNFR2 may also contribute to TNFR1-
mediated proinflammatory responses.31e32
Several studies have reported an association of the
TNFRSF1B þ 676 SNP with susceptibility to several inflam-
matory diseases such as systemic lupus erythematosus,33
rheumatoid arthritis,34 and Crohn’s disease in humans.35
Moreover, a recent study has found an association between
the TNFRSF1B þ 676 SNP and response to infliximab.36 The
TNFRSF1B þ 676 SNP results in a change of methionine to
arginine at codon 196 (M196R) located in close proximity to
the proteolytic cleavage site, which is crucial for the
shedding of TNFR2, and could condition soluble TNFR2
levels.37,38 In addition, the TNFR2-196R variant, encoded by
the G allele, was shown to have a lower capacity to induce
direct NF-kB signalling via TNFR2, leading to a diminished
induction of NF-kB-dependent target genes involved in anti-
apoptotic and pro-inflammatory functions.39 Our studysuggests a protective role of heterozygosity at the
TNFRSF1B þ 676 SNP in the outcome of CAP. However,
homozygosity for the wild-type TNFRSF1B þ 676 T allele
was associated with a trend towards protection from the
development of MODS. Increased levels of NF-kB activation
have been associated with a worse outcome from
sepsis.40,41 Likewise, in our experience, TLR-mediated
primary immunodeficiencies (PID) such as IRAK-4 and MyD88
deficiencies, leading to decreased NF-kB activation, confer
a high susceptibility to invasive infections by S. pneumoniae
and S. aureus, and in a lesser extent to P. aeruginosa.42,43
However, patients with these PID show a low clinical and
biological inflammatory response in the course of the
infections, and in fact their condition has been referred to
as septicaemia without sepsis.42,43 The protective role of
heterozygosity at TNFRSF1B þ 676 in the outcome of sepsis
could thus be due to a counterbalance of the deleterious
consequences of excessive or impaired NF-kB activation
conferred by the genotype homozygous for the wild-type or
mutant alleles, respectively.44
To date only one study20 has investigated the role of
TNFR2 receptor polymorphisms (þ676 and þ1663) in 213
patients with severe sepsis. The authors found a positive
correlation between increasing soluble TNFR1 and TNFR2
levels and organ dysfunction, but there was no influence of
TNFRSF1B SNPs either on soluble TNFR2 levels or in
susceptibility to and outcome from sepsis. Possible reasons
for the discrepancy with the data from Gordon et al.21 are
the clinical phenotype and their smaller sample size.
In spite of the above-mentioned strengths of our
study, we acknowledge some limitations. First, although
current recommendations for treatment of sepsis and
septic shock were applied, a common protocol was not
specifically used. Second, only six polymorphisms of five
mediators were determined. The functional importance
of many of these polymorphisms remains to be eluci-
dated, and many SNPs may simply represent genomic
markers for other more functionally relevant genetic
variants in linkage disequilibrium. Third, although our
study could be underpowered to detect statistically
significant differences for the less frequent genotypes,
particularly in small subgroups or patients, a substantial
number of patients (325, 28%) developed severe forms of
sepsis. Nevertheless the sample size is sufficient to
detect odds ratios of 1,49, 1,38, 1,29, 1,27 and 1,28 for
the TNF 238 A, TNF 308 A, LTA þ252 G and, IL6 174
and IL1RN*2 alleles respectively at a significance
threshold of 0.05 with 80% power. These are the alleles
previously reported to be involved in sepsis severity,
usually with higher OR. In addition, when the association
of TNFRSF1B þ 676 G/T genotype with 28-day mortality
was analysed, the statistical power for the observed odd-
ratio, with a significance level of 5%, was 93%. Despite all
these limitations, this study is unique in having an
ethnically homogeneous population of patients admitted
to the hospital with CAP, and evaluating the factors
associated with severity and mortality from the time of
their admission to the hospital.
In conclusion, our study does not support a role of the
controversial polymorphisms of TNF, LTA, IL6 and IL1RN in
CAP and sepsis, at least in our population. However, it
points towards a role of the TNFRSF1B þ 676 SNP in CAP
446 J. Sole´-Viola´n et al.outcome, which could potentially identify a subgroup of
patients who may benefit from standard TNF-a and LT-
a modulatory therapies.
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APACHE II Acute Physiology and Chronic Health
Evaluation
ARDS acute respiratory distress syndrome
ARF acute respiratory failure
CAP community-acquired pneumonia
CI confidence intervals
HR hazard ratio
ICU intensive care unit
IL-6 interleukin-6
IL6 IL-6 gene
IL1RA interleukin-1 receptor antagonistIL1RN interleukin-1 receptor antagonist gene
LD linkage disequilibrium
LT-a lymphotoxin-alpha
LTA lymphotoxin alpha gene
MODS multiple organ dysfunction syndrome
OR odds ratio
PID primary immunodeficiencies
PIRO predisposition, insult, response, organ
dysfunction
PSI pneumonia severity index
SNP single nucleotide polymorphism
SS severe sepsis
SSh septic shock
TNF-a tumor necrosis factor-a
TNF tumor necrosis factor alpha gene
TNFR2 tumor necrosis factor receptor 2
TNFRSF1B TNFR2 gene
VNTR variable number of tandem repeatReferences
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